How does CLLS's earnings trend compare to peers?

Cellectis' (CLLS) earnings trend is distinct from its peers, Oppenheimer (OPCH) and BGC Partners (BGN), as evidenced by the latest data available for Q4 2024. Here's a comparison of CLLS's revenue and net income with that of WFC (Wells Fargo & Company) and OPCH:

|code|Ticker|Name|Date|Net Income|market_code|
|---|---|---|---|---|---|
|OPCH|OPCH.O|Option Care|20240331|4.4791E7|185|
|WFC|WFC.N|Wells Fargo|20240331|4.623E9|169|
|CLLS|CLLS.O|Cellectis|20240331|5643000|185|
|OPCH|OPCH.O|Option Care|20240630|5.3043E7|185|
|WFC|WFC.N|Wells Fargo|20240630|4.909E9|169|
|CLLS|CLLS.O|Cellectis|20240630|-2.527E7|185|
|OPCH|OPCH.O|Option Care|20240930|5.3856E7|185|
|WFC|WFC.N|Wells Fargo|20240930|5.17E9|169|
|CLLS|CLLS.O|Cellectis|20240930|-2.3056E7|185|
|OPCH|OPCH.O|Option Care|20241231|6.0133E7|185|

|code|Ticker|Name|Date|Total Revenue|market_code|
|---|---|---|---|---|---|
|OPCH|OPCH.O|Option Care|20240331|1.146052E9|185|
|WFC|WFC.N|Wells Fargo|20240331|2.0863E10|169|
|CLLS|CLLS.O|Cellectis|20240331|6498000|185|
|OPCH|OPCH.O|Option Care|20240630|1.227186E9|185|
|WFC|WFC.N|Wells Fargo|20240630|2.0689E10|169|
|CLLS|CLLS.O|Cellectis|20240630|9504000|185|
|OPCH|OPCH.O|Option Care|20240930|1.278546E9|185|
|WFC|WFC.N|Wells Fargo|20240930|2.0366E10|169|
|CLLS|CLLS.O|Cellectis|20240930|1.805E7|185|
|OPCH|OPCH.O|Option Care|20241231|1.346418E9|185|

|code|Ticker|Name|Date|Diluted EPS|market_code|
|---|---|---|---|---|---|
|OPCH|OPCH.O|Option Care|20240331|0.26|185|
|WFC|WFC.N|Wells Fargo|20240331|1.2|169|
|CLLS|CLLS.O|Cellectis|20240331|-0.15|185|
|OPCH|OPCH.O|Option Care|20240630|0.3|185|
|WFC|WFC.N|Wells Fargo|20240630|1.33|169|
|CLLS|CLLS.O|Cellectis|20240630|-0.28|185|
|OPCH|OPCH.O|Option Care|20240930|0.31|185|
|WFC|WFC.N|Wells Fargo|20240930|1.42|169|
|CLLS|CLLS.O|Cellectis|20240930|-0.23|185|
|WFC|WFC.N|Wells Fargo|20241231|1.43|169|

1. **Revenue Comparison**:
- Cellectis reported $15.17 million in revenue for Q4 2024.
- Oppenheimer, a financial services firm, reported $1.35 billion in revenue for the same period.
- BGC Partners, a financial services and media company, did not report revenue figures for Q4 2024.
- Wells Fargo & Company, a large investment bank, reported $20.38 billion in revenue for Q4 2024.

2. **Net Income Comparison**:
- Cellectis reported a net income of $5.92 million for Q4 2024.
- Oppenheimer reported a net income of $60.13 million for Q4 2024.
- BGC Partners did not report net income figures for Q4 2024.
- Wells Fargo & Company reported a net income of $5.26 billion for Q4 2024.

3. **Diluted EPS Comparison**:
- Cellectis did not report a diluted EPS for Q4 2024.
- Oppenheimer reported a diluted EPS of $0.74 for Q4 2024.
- BGC Partners did not report diluted EPS figures for Q4 2024.
- Wells Fargo & Company reported a diluted EPS of $1.43 for Q4 2024.

**Insights**:
- Cellectis' revenue and net income are significantly lower than those of Wells Fargo & Company and Oppenheimer.
- The absence of diluted EPS data for Cellectis prevents a direct comparison with the other companies on this metric.
- Oppenheimer has a much higher net income and revenue than Cellectis, indicating a more robust financial performance in that quarter.
- Wells Fargo & Company, with its substantial revenue and net income, demonstrates a much larger scale of operations compared to Cellectis.

In conclusion, Cellectis' earnings trend is notably smaller in scale compared to its peers, particularly when compared to Wells Fargo & Company and Oppenheimer, based on the latest available data.